-
公开(公告)号：US20220091136A1
公开(公告)日：2022-03-24
申请号：US17475753
申请日：2021-09-15
Inventor： You-Sun KIM , Siyoung YANG
IPC: G01N33/68
Abstract: Disclosed is the novel use of TRIM24 and RIP3 as biomarkers for diagnosing osteoarthritis, in which it is first identified that TRIM24 and RIP3 can be used as biomarkers for diagnosing osteoarthritis by confirming the tendency of TRIM24 expression to decrease and RIP3 expression to increase at the onset of osteoarthritis. These two proteins are useful in confirming the change in the expression level from the onset of osteoarthritis, thus enabling early diagnosis of osteoarthritis and effectively blocking the progression of osteoarthritis at an early stage.
-
公开(公告)号：US20230285433A1
公开(公告)日：2023-09-14
申请号：US18086971
申请日：2022-12-22
Inventor： You-Sun KIM , Sun Mi HONG , A-Yeon LEE
IPC: A61K31/706 , A61P29/00
CPC classification number: A61K31/706 , A61P29/00
Abstract: The present disclosure relates to a pharmaceutical composition for treating or preventing inflammatory diseases including nicotinamide mononucleotide (NMN) as an active ingredient. When NAMPT was knocked out, removal of dead cells for tissue repair was failed, which leads to a significant increase in susceptibility to colitis, whereby systemic administration of NMN to supply NAD+ can effectively suppress inflammatory severity, making it a potential therapeutic strategy for managing inflammatory diseases.
-
公开(公告)号：US20180231553A1
公开(公告)日：2018-08-16
申请号：US15750421
申请日：2016-05-07
Inventor： You-Sun KIM , Gi Bang KOO
IPC: G01N33/574 , A61K38/45 , A61K47/66 , A61P35/00
CPC classification number: G01N33/574 , A61K31/282 , A61K31/404 , A61K31/506 , A61K31/704 , A61K31/7048 , A61K31/7068 , A61K33/24 , A61K38/45 , A61K47/66 , A61K2300/00 , A61P35/00 , G01N33/5011 , G01N33/57496
Abstract: The present invention relates to a pharmaceutical composition for an anticancer adjuvant comprising a receptor-interacting protein kinase-3 (RIP3) protein expression promotor or activator as an active ingredient. In addition, the present invention provides a method of promoting cancer cell apoptosis, characterized by co-administering an anticancer agent and a RIP3 protein expression promotor or activator to cancer cells. Also, the present invention relates to a method for screening an anticancer adjuvant which promotes RIP3 expression and enhances sensitivity of an anticancer agent, and a method for monitoring sensitivity of an anti-cancer agent depending on the RIP3 expression. Accordingly, in the case of a patient lacking the expression of RIP3, it is expected to be an effective treatment strategy to pre-treat a demethylating agent to induce the expression of RIP3 and then to use a conventional chemotherapeutic agent. In addition, in chemotherapy, it is anticipated that the present invention may be an effective strategy in screening an anticancer adjuvant which monitors and enhances sensitivity of an anticancer agent.
-
-
Search Results
3
records
(took 0.015 seconds)
